Concerns, Catalysts & Risks -- 7/10
A mature, cyclical materials/commodity producer. Primary valuation metric is EV/EBITDA (P/E is
distorted by the 2026 trough and large non-cash charges). The setup is a classic sentiment-inversion
candidate: a deeply de-rated cyclical trading below book value and well under peers (~2.9x forward
EV/EBITDA vs ~6-8x), with real near-term catalysts (phosphate supply tightness, record Canpotex potash
pace, self-help capital discipline) offset by a murky near-term operating picture and a geopolitical
overhang on raw materials. Scores 7 on deep discount plus identifiable catalysts, but held short of the
top band by withdrawn guidance, a major EPS miss, negative TTM FCF, and event-dependent recovery.
Weight: 15%
Valuation
~2.9x
Fwd EV/EBITDA vs ~6-8x peers
Below book value
Consensus
Hold
~$26 target vs $22.43
Skeptical, downward revisions
Guidance
Withdrawn
FY phosphate + Q2 Fert pulled
Low visibility
China Exposure
Favorable
Net supply-side beneficiary
Export ban tightens supply
Valuation -- Primary Metric: Forward EV/EBITDA
| Metric | Estimate | Multiple | Peer Avg |
|---|---|---|---|
| EV / FY26E EBITDA (primary) | EBITDA ~$2.78B | ~2.9x | ~6-8x |
| EV / EBITDA (TTM) | TTM EBITDA ~$2.40B | ~3.36x | Industry ~5.24x |
| EV / FY27E EBITDA | EBITDA ~$2.78B | ~2.9x | — |
| Price / Book (TTM) | Below book | ~0.60x | — |
Valuation is unambiguously below peer average.
MOS at ~2.9x forward / ~3.36x TTM EV/EBITDA sits at the bottom of the historical and peer range — a
deep discount to Nutrien (~8.1x) and CF, and below the industry median (5-yr median ~10.18x). It
also trades below book value (~0.60x P/B). The catch: this is priced off a depressed-but-recovering
earnings base — Adj EBITDA collapsed from $806M (Q3'25) to $416M (Q1'26) — so the EBITDA trajectory,
not the absolute multiple, is the swing factor. Cheap can stay cheap through a full cycle.
Catalysts
| # | Catalyst | Timing / Read |
|---|---|---|
| 1 | Strait of Hormuz / sulfur normalization | Near-term, event-driven. Largest single swing — restores stripping margins; management frames current ~$1,200/t marginal sulfur as unsustainable and temporary. |
| 2 | Phosphate structural tightness + China export ban | Ongoing through 2026. China banned phosphate exports through August; "not going to be enough phosphate to meet global demand"; under-application sets up demand normalization. |
| 3 | Canpotex potash sold out, record 2026 pace | H2'26 weighted. Durable potash EBITDA (~$275M Q1'26); record 2H international shipments guided. |
| 4 | Capital discipline / self-help | 2026, building. FY26 CapEx cut $250M to $1.25B; $50M new + $100M prior cost programs; workforce reduction — protects FCF through the trough. |
| 5 | Portfolio reshaping | Completed/underway. Carlsbad mine sale (closed April), Araxa/Patrocinio idling, three mines sold — sheds sub-hurdle SSP assets, lowers maintenance capex $20-30M/yr. |
| 6 | Growth optionality | Multi-year. Mosaic Biosciences (revenue to double in 2026, 8-10 launches), Rainbow Rare Earths agreement at Uberaba gyp stack — small today, free options on the asset base. |
China Exposure & Regulatory / Political Risk
| # | Risk | Severity | Detail |
|---|---|---|---|
| 1 | Geopolitical supply disruption | HIGH | Persian Gulf / Strait of Hormuz + Black Sea flows have impaired ~half of global phosphate raw materials and seaborne sulfur. Cuts both ways — crushed Q1'26 margins but drives the pricing tightness underpinning the recovery. |
| 2 | China exposure | FAVORABLE | Low direct demand risk (well under 10%); largest revenue geography is Brazil. Net supply-side beneficiary — China's phosphate export ban tightens global supply and is a tailwind to realizations. |
| 3 | Brazil credit / FX | MEDIUM | Mosaic Fertilizantes EBITDA fell to $79M; 2026 Brazil fertilizer use likely contracts on nutrient availability and affordability. |
| 4 | Farmer affordability | LOW-MEDIUM | U.S./Brazil farmer affordability caps price pass-through as a price-taker. |
| 5 | Company-specific regulatory | LOW | No antitrust, product ban, or litigation cited. Reshoring/fiscal policy broadly neutral-to-favorable. |
Bull case
| # | Factor | Detail |
|---|---|---|
| 1 | Trough Multiple on Trough Number | ~2.9x forward EV/EBITDA and below book value. If sulfur normalizes, EBITDA snaps back toward $2.7B+ consensus and both the multiple and earnings re-rate. |
| 2 | Structural Phosphate Tightness | Tight even before the Gulf conflict; under-application of nutrients builds latent demand; China's export ban and global curtailments tighten supply further. |
| 3 | Durable Potash Cash Engine | Canpotex sold out, ~$275M Q1'26 EBITDA, record 2H pace. The stable leg while phosphate recovers. |
| 4 | Self-Help + Low Leverage | CapEx cut, $150M cost programs, asset sales protect FCF; ~0.4x net debt/EBITDA gives staying power through the trough. |
| 5 | Free Options | Mosaic Biosciences and Rainbow Rare Earths at Uberaba are small today but embedded optionality on the asset base. |
Bear case
| # | Factor | Detail |
|---|---|---|
| 1 | Value Trap on Melting Earnings | Adj EPS fell to $0.05 in Q1'26 vs $0.20 Street (major miss); GAAP EPS -$0.81. The cheap multiple sits on a shrinking base. |
| 2 | Guidance Withdrawn | FY phosphate production and Q2 Fertilizantes EBITDA guidance both pulled — the classic red-flag cluster (guidance pulled, defensive tone, margin collapse, negative TTM FCF). |
| 3 | Recovery Hostage to Geopolitics | The thesis depends on a Hormuz/sulfur resolution no one can time. If protracted, sulfur stays at ~$1,200/t and the producer cost curve stays underwater. |
| 4 | Not Earning Cost of Capital | ROIC ~1.4% today; Brazil contracting; farmer affordability caps phosphate pricing. "Cheap" can stay cheap for a full cycle. |
| 5 | Price-Taker, No Spread Control | Q1'26 proved Mosaic cannot dictate spread — phosphate EBITDA collapsed to ~$115M despite a strong DAP price as input costs squeezed margins. |
Score rationale
Score of 7/10. The rubric is dominated by valuation, and here it is a clear positive: MOS trades below peer average at ~2.9x forward EV/EBITDA (vs ~6-8x peers) and below book value.
Why this high: Deep valuation discount (strong positive); low/favorable China exposure — sub-10% demand dependence and a net supply-side beneficiary of China's export ban (positive); a genuine, identifiable slate of catalysts (phosphate structural tightness, record Canpotex pace, self-help capital discipline); no company-specific regulatory overhang.
Why not higher: The dominant near-term catalyst (sulfur normalization) is event-dependent on an uncontrollable geopolitical resolution; management withdrew FY phosphate production and Q2 Fertilizantes EBITDA guidance after a major Q1'26 EPS miss ($0.05 vs $0.20 Street); TTM FCF is negative; consensus EPS troughs at $0.81 in 2026 before recovering to ~$1.9 in 2027.
Net: A quality, oligopolistic franchise trading at a trough multiple on a trough number, with real catalysts — but withdrawn guidance, a melting near-term earnings base, and a geopolitical dependency keep it short of the 9-10 band. 7/10.
Data sourced from Daloopa (company_id 492), FMP (market/valuation/consensus), the MOS FY2026Q1 transcript, and web research (peer/industry multiples). Current price $22.43 (FMP, 2026-06-29).